Synthesis, Characterization, and in Vitro Antitumor Activity of Osteotropic Diam(m)ineplatinum(II) Complexes Bearing a N,N-Bis(phosphonomethyl)glycine Ligand

Journal of Medicinal Chemistry

Volumn 46, Issue 23, 2003, Pages 4946-4951

  Galanski, Markus ^a   Slaby, Susanna ^a   Jakupec, Michael A ^a   Keppler, Bernhard K ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOHEXANE 1,2 DIAMINE; DIAMINE DERIVATIVE; ETHANE 1,2 DIAMINE; LIGAND; N,N BIS(PHOSPHONOMETHYL)GLYCINE LIGAND; OXALIPLATIN; PLATINUM COMPLEX; UNCLASSIFIED DRUG; [[BIS(PHOSPHONOMETHYL)AMINO KAPPA N] ACETATO KAPPA O (2-)](CYCLOHEXANE 1,2 DIAMINE)PLATINUM; [[BIS(PHOSPHONOMETHYL)AMINO KAPPA N] ACETATO KAPPA O (2-)]PLATINUM;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CARBON NUCLEAR MAGNETIC RESONANCE; CONTROLLED STUDY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; OVARY CANCER; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PROTON NUCLEAR MAGNETIC RESONANCE; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

EID: 0242299584     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0308040     Document Type: Article

References (30)

1. Rosenberg, B.; VanCamp, L.; Krigas, T. Inhibiton of Cell Division in Escherichia Coli by Electrolysis Products From a Platinum Electrode. Nature 1965, 205, 698-699.
2. Rosenberg, B.; VanCamp, L.; Trosko, J. E.; Mansour, V. H. Platinum Compounds: A New Class of Potent Antitumour Agents. Nature 1969, 222, 385-386.
3. Rosenberg, B. Platinum Complexes for the Treatment of Cancer. Interdiscip. Sci. Rev. 1978, 3 (2), 134-147.
4. Lippert, B., Ed. Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug; Verlag Helvetica Chimica Acta: Zürich, Switzerland, and Wiley-VCH: Weinheim, Germany, 1999.
5. O'Dwyer, P. J.; Stevenson, J. P.; Johnson, S. W. Clinical Pharmacokinetics and Administration of Established Platinum Drugs. Drugs 2000, 59 (Suppl. 4), 19-27.
6. O'Dwyer, P. J.; Stevenson, J. P.; Johnson, S. W. Clinical Status of Cisplatin, Carboplatin, and Other Platinum-Based Antitumor Drugs. In Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug; Lippert, B., Ed.; Verlag Helvetica Chimica Acta: Zürich, Switzerland, and Wiley-VCH: Weinheim, Germany, 1999; pp 31-69.
7. Jakupec, M. A.; Galanski, M.; Keppler, B. K. Tumour-Inhibiting Platinum Complexes - State of the Art and Future Perspectives. Rev. Physiol. Biochem. Pharmacol. 2003, 146, 1-53.
8. Hall, M. D.; Hambley, T. W. Platinum(IV) Antitumour Compounds: Their Bioinorganic Chemistry. Coord. Chem. Rev. 2002, 232, 49-67.
9. Hambley, T. W. The Influence of Structure on the Activity and Toxicity of Pt Anti-Cancer Drugs. Coord. Chem. Rev. 1997, 166, 181-223.
10. Paterson, A. H. G. Bisphosphonates: Biological Response Modifiers in Breast Cancer. Clin. Breast Cancer 2002, 3, 206-216.
11. Powles, T.; Paterson, S.; Kanis, J. A.; McCloskey, E.; Ashley, S.; Tidy, A.; Rosenqvist, K.; Smith, I.; Ottestad, L.; Legault, S.; Pajunen, M.; Nevantaus, A.; Mannisto, E.; Suovuori, A.; Atula, S.; Nevalainen, J.; Pylkkanen, L. Randomized, Placebo-Controlled Trial of Clodronate in Patients with Primary Operable Breast Cancer. J. Clin. Oncol. 2002, 20, 3219-3224.
12. Wingen, F.; Sterz, H.; Blum, H.; Moeller, H.; Pittermann, W.; Pool, B. L.; Sinn, H. J.; Spring, H.; Schmaehl, D. Synthesis, Antitumor Activity, Distribution and Toxicity of 4-[4-[Bis(2-chloroethyl)amino]phenyl]-1-hydroxybutane-1,1-bisphosphonic Acid (BAD), a New Lost Derivative with Increased Accumulation in Rat Osteosarcoma. J. Cancer Res. Clin. Oncol. 1986, 111, 209-219.
13. Galanski, M.; Slaby, S.; Keppler, B. K. The Mode of Action of Antitumor Platinum Compounds Linked to Amino Phosphonic Acids With Particular Activity Against Bone Malignancies and the Influence of Calcium Ions onto the DNA Binding Behavior. In Relevance of Tumor Models for Anticancer Drug Development; Fiebig, H. H., Burger, A. M., Eds. In Contributions to Oncology; Queisser, W., Scheithauer, W., Eds.; Karger: Basel, 1999; Vol. 54, pp 435-438.
14. Klenner, T.; Wingen, F.; Keppler, B. K.; Krempien, B.; Schmaehl, D. Anticancer-Agent-Linked Phosphonates with Antiosteolytic and Antineoplastic Properties: A Promising Perspective in the Treatment of Bone-Related Malignancies? J. Cancer Res. Clin. Oncol. 1990, 116, 341-350.
15. Klenner, T.; Wingen, F.; Keppler B.; Valenzuela-Paz, P.; Amelung, F.; Schmähl, D. Therapeutic Efficacy of Two Different Cytostatic-Linked Phosphonates in Combination with Razoxane in the Transplantable Osteosarcoma of the Rat. Clin. Exp. Metastasis 1990, 8, 345-359.
16. Klenner, T.; Valenzuela-Paz, P.; Amelung, F.; Muench, H.; Zahn, H.; Keppler, B. K.; Blum, H. Platinum Phosphonato Complexes with Particular Activity Against Bone Malignancies. Evaluation of an Experimental Tumor Model Highly Predictive for the Clinical Situation. In Metal Complexes in Cancer Chemotherapy; Keppler, B. K., Ed.; VCH: Weinheim, 1993; pp 85-127.
17. Klenner, T.; Valenzuela-Paz, P.; Keppler, B. K.; Scherf, H. R. Sensitivity of Rodent Osteosarcoma Clones to Platinum-Containing Phosphonic Acid Complexes in Vitro. J. Cancer Res. Clin. Oncol. 1990, 116, 453-458.
18. Slaby, S.; Galanski, M.; Metzger, S. W.; Keppler, B. K. Design of Platinum Complexes with High Affinity for Osteosarcoma and Bone Metastases - Structure-Activity Relationship. In Relevance of Tumor Models for Anticancer Drug Development; Fiebig, H. H., Burger, A. M., Eds. In Contributions to Oncology; Queisser, W., Scheithauer, W., Eds.; Karger: Basel, 1999; Vol. 54, pp 201-205.
19. Kersten, L.; Bräunlich, H.; Keppler, B. K.; Gliesing, C.; Wendelin, M.; Westphal, J. Comparative Nephrotoxicity of Some Antitumour-Active Platinum and Ruthenium Complexes in Rats. J. Appl. Toxicol. 1998, 18, 93-101.
20. Woynarowski, J. M.; Faivre, S.; Herzig, M. C. S.; Arnett, B.; Chapman, W. G.; Trevino, A. V.; Raymond, E.; Chaney, S. G.; Vaisman, A.; Varchenko, M.; Juniewicz, P. E. Oxaliplatin-Induced Damage of Cellular DNA. Mol. Pharmacol. 2000, 58, 920-927.
21. Chaney, S. G.; Vaisman, A. DNA Adduct Tolerance and Bypass. In Platinum-Based Drugs in Cancer Therapy; Kelland, L. R., Farrell, N. P., Eds.; Humana Press: Totowa, New Jersey, 2000; pp 129-148.
22. 2]. Indian J. Chem. 1970, 8, 193-194.
23. Kidani, Y.; Inagaki, K.; Iigo, M.; Hoshi, A.; Kuretani, K. Antitumor Activity of 1,2-Diaminocyclohexane Platinum Complexes Against Sarcoma-180 Ascites Form. J. Med. Chem. 1978, 21, 1315-1318.
24. Pendyala, L.; Kidani, Y.; Perez, R.; Wilkes, J.; Bernacki, R. J.; Creaven, P. J. Cytotoxicity, Cellular Accumulation and DNA Binding of Oxaliplatin Isomers. Cancer Lett. 1995, 97, 177-184.
25. Kido, Y.; Khokhar, A. R.; Al-Baker, S.; Siddik, Z. H. Modulation of Cytotoxicity and Cellular Pharmacology of 1,2-Diaminocyclohexane Platinum(IV) Complexes Mediated by Axial and Equatorial Ligands. Cancer Res. 1993, 53, 4567-4572.
26. Noji, M.; Okamoto, K.; Kidani Y. Relation of Conformation to Antitumor Activity of Platinum(II) Complexes of 1,2-Cyclohexanediamine and 2-(Aminomethyl)cyclohexylamine Isomers against Leukemia P388. J. Med. Chem. 1981, 24, 508-515.
27. Siddik, Z. H.; Al-Baker, S.; Thai, G.; Khokhar, A. R. Antitumor Activity of Isomeric 1,2-Diaminocyclohexane Platinum(IV) Complexes. J. Cancer Res. Clin. Oncol. 1994, 120, 409-414.
28. Siddik, Z. H.; Al-Baker, S.; Burditt, T. L.; Khokhar, A. R. Differential Antitumor Activity and Toxicity of Isomeric 1,2-Diaminocyclohexane Platinum (II) Complexes. J. Cancer Res. Clin. Oncol. 1993, 120, 12-16.
29. Mamenta, E. L.; Poma, E. E.; Kaufmann, W. K.; Delmastro, D. A.; Grady, H. L.; Chaney, S. G. Enhanced Replicative Bypass of Platinum-DNA Adducts in Cisplatin-Resistant Human Ovarian Carcinoma Cell Lines. Cancer Res. 1994, 54, 3500-3505.
30. Kraker, A. J.; Moore, C. W. Accumulation of cis-Diamminedichloroplatinum(II) and Platinum Analogues by Platinum-Resistant Murine Leukemia Cells in Vitro. Cancer Res. 1988, 48, 9-13.